MNPR - Monopar a new overweight at Piper Sandler on rare disease asset
2025-03-19 10:27:11 ET
More on Monopar Therapeutics
- Monopar Therapeutics: Strong Data, But There Are Risks
- Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
- Monopar Therapeutics announces pricing of $40M public offering of common stock
- Seeking Alpha’s Quant Rating on Monopar Therapeutics
- Historical earnings data for Monopar Therapeutics